UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstracts for References 2-5

of 'Congenital rubella syndrome: Management, outcome, and prevention'

2
TI
Hypogammaglobulinemia in an infant with congenital rubella syndrome; failure of 1-adamantanamine to stop irus excretion.
AU
Plotkin SA, Klaus RM, Whitely JP
SO
J Pediatr. 1966;69(6):1085.
 
AD
PMID
3
TI
Alpha interferon administration to infants with congenital rubella.
AU
Arvin AM, Schmidt NJ, Cantell K, Merigan TC
SO
Antimicrob Agents Chemother. 1982;21(2):259.
 
Three infants with congenital rubella syndrome were given human leukocyte (alpha) interferon at doses of 2 x 10(5) to 7 X 10(5) U/kg per day for 10 days. A transient decrease in pharyngeal virus excretion was observed with treatment. No significant side effects were associated with the administration of human leukocyte interferon to these infants.
AD
PMID
4
TI
Administration of interferon to an infant with congenital rubella syndrome involving persistent viremia and cutaneous vasculitis.
AU
Larsson A, Forsgren M, Hård af Segerstad S, Strander H, Cantell K
SO
Acta Paediatr Scand. 1976;65(1):105.
 
AD
PMID
5
 
 
Plotkin, SA, Reef, et al. Rubella. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, Klein, JO, Wilson, CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.861.
 
no abstract available